Napsin A as a key prognostic biomarker in spinal metastases of lung cancer: implications for survival and neurological function
Somatic mutations in EGFR and KRAS and expression of napsin A and CK7 significantly influence survival in patients with LCSM. Mutations in EGFR and expression of napsin A, along with targeted therapy, were associated with better patient outcomes, emphasizing the need for personalized treatment strategies to improve survival and neurological function.
Authors
- Daniel Lubelski (ORCID: https://orcid.org/0000-0002-9403-9509)
- Kristin J. Redmond (ORCID: https://orcid.org/0000-0003-3442-4613)
- Timothy F. Witham (ORCID: https://orcid.org/0000-0002-9397-8344)
- Albert Antar (ORCID: https://orcid.org/0000-0002-3169-8873)
- A. Daniel Davidar (ORCID: https://orcid.org/0000-0002-1508-3449)
- Melanie Alfonzo Horowitz (ORCID: https://orcid.org/0000-0002-4935-7268)
- Abdel‐Hameed Al‐Mistarehi (ORCID: https://orcid.org/0000-0003-4713-8536)
- Nicholas Theodore (ORCID: https://orcid.org/0000-0001-5355-2683)
- Yuanxuan Xia (ORCID: https://orcid.org/0000-0001-6152-8392)
- Carly Weber-Levine (ORCID: https://orcid.org/0000-0003-2057-8419)
- Ali Bydon (ORCID: https://orcid.org/0000-0002-3058-1470)
- Mark H. Bilsky (ORCID: https://orcid.org/0000-0001-6091-0709)
- Shahab Aldin Sattari (ORCID: https://orcid.org/0000-0002-4021-3153)
- Sang Hun Lee (ORCID: https://orcid.org/0000-0001-5942-8309)
- Pritika Papali
- Sushanth Neerumalla (ORCID: https://orcid.org/0009-0007-9561-8688)
- Shreya Sriram
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- Neurosurgical FOCUS
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3171/2025.2.focus24897
- Primary Topic
- Management of metastatic bone disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00